PL446899A1 - Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration - Google Patents

Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration

Info

Publication number
PL446899A1
PL446899A1 PL446899A PL44689923A PL446899A1 PL 446899 A1 PL446899 A1 PL 446899A1 PL 446899 A PL446899 A PL 446899A PL 44689923 A PL44689923 A PL 44689923A PL 446899 A1 PL446899 A1 PL 446899A1
Authority
PL
Poland
Prior art keywords
risk
death
cancer
determining
concentration
Prior art date
Application number
PL446899A
Other languages
Polish (pl)
Inventor
Adam Kiljańczyk
Milena Matuszczak
Wojciech MARCINIAK
Róża Derkacz
Klaudia Stempa
Piotr Baszuk
Marta Bryśkiewicz
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Tadeusz Dębniak
Marcin Lener
Anna Jakubowska
Marek Szwiec
Małgorzata Stawicka-Niełacna
Dariusz Godlewski
Artur Prusaczyk
Andrzej Jasiewicz
Joanna Tomiczek-Szwiec
Ewa Kilar-Kobierzycka
Monika Siołek
Rafał Wiśniowski
Renata Posmyk
Joanna Tretyn-Jarkiewicz
Krzysztof Dach
Steven Alexander Narod
Jan LUBIŃSKI
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL446899A priority Critical patent/PL446899A1/en
Publication of PL446899A1 publication Critical patent/PL446899A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zachorowania na raka i zgonu u kobiet, będących nosicielkami mutacji w genie BRCA1, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia ołowiu we krwi osoby badanej, przy czym stężenie wskazuje na ponad 1,5 krotnie zmniejszone ryzyko zachorowania na raka o różnej lokalizacji, w stosunku do podgrupy ze stężeniem ołowiu we krwi >16,98 µg/l, w przypadku występowania wartości stężenia ołowiu we krwi <9,59 µg/l. Natomiast ryzyko zgonu przy tych samych stężeniach ołowiu jest 3 krotnie zmniejszone.The subject of the application is a method for determining the risk of cancer and death in women who are carriers of mutations in the BRCA1 gene, characterized in that it includes a quantitative assessment of the concentration of lead in the blood of the tested person, where the concentration indicates a more than 1.5-fold reduced risk of cancer of various locations, in relation to the subgroup with a blood lead concentration of >16.98 µg/l, in the case of a blood lead concentration value of <9.59 µg/l. On the other hand, the risk of death at the same lead concentrations is reduced 3-fold.

PL446899A 2023-11-29 2023-11-29 Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration PL446899A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL446899A PL446899A1 (en) 2023-11-29 2023-11-29 Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446899A PL446899A1 (en) 2023-11-29 2023-11-29 Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration

Publications (1)

Publication Number Publication Date
PL446899A1 true PL446899A1 (en) 2025-06-02

Family

ID=95857893

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446899A PL446899A1 (en) 2023-11-29 2023-11-29 Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration

Country Status (1)

Country Link
PL (1) PL446899A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL422787A1 (en) * 2017-09-08 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum
PL433150A1 (en) * 2020-03-05 2021-09-06 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL422787A1 (en) * 2017-09-08 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum
PL433150A1 (en) * 2020-03-05 2021-09-06 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level

Similar Documents

Publication Publication Date Title
Carr et al. Discrepancies in global vitamin C recommendations: A review of RDA criteria and underlying health perspectives
Pirola et al. Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: Results of the SETI study
Ding et al. Longitudinal trends in perfluoroalkyl and polyfluoroalkyl substances among multiethnic midlife women from 1999 to 2011: The Study of Women′ s Health Across the Nation
Waring et al. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study
Rahman et al. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?
O’Flaherty et al. Phosphorylation of the Arginine‐X‐X‐(Serine/Threonine) motif in human sperm proteins during capacitation: Modulation and protein kinase A dependency
Holmes et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates
PL440972A1 (en) Method of determining the risk of cancer in women depending on the ratio of selenium to arsenic concentrations in blood
Fiuza et al. Impact of SIN-1-derived peroxynitrite flux on endothelial cell redox homeostasis and bioenergetics: protective role of diphenyl diselenide via induction of peroxiredoxins
Honkanen et al. The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy
Hjollund et al. Job strain and male fertility
Yakub et al. Association of blood lead (Pb) and plasma homocysteine: a cross sectional survey in Karachi, Pakistan
PL437046A1 (en) Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
Schmidt et al. High androgen levels protect against hypothyroidism
Goodrose-Flores et al. High-protein compared with standard parenteral nutrition in palliative cancer care
Cázares-Preciado et al. Metabolic features of neutrophilic differentiation of HL-60 cells in hyperglycemic environments
Liu et al. Risk factors for thyroid function test abnormalities during pregnancy: a systematic review of the literature to validate current risk factors and identify novel ones
PL447789A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood
PL438038A1 (en) Method of determining risk of cancer in women depending on age, history of smoking and selenium concentration in the blood
PL447790A1 (en) Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood
PL448873A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the ratio of zinc to copper concentrations in whole blood
PL441999A1 (en) Method of determining the risk of cancer in men depending on the ratio of concentrations of selected elements in the blood
PL447813A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of zinc in whole blood
Tzivian et al. The death and owning of the companion dog: Association between resource loss and stress in healthy Israeli women
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level